WASHINGTON — The pharmaceutical industry made it clear to the Food and Drug Administration that it wants the regulatory flexibilities the agency has embraced during the Covid-19 pandemic to be made permanent — and it’s ready to push to make sure it happens.
“There is a pressing need for FDA and industry to identify actions taken during the Covid-19 pandemic and evaluate their effectiveness and applicability to innovative drug development beyond the public health emergency,” said Lucy Vereshchagina, vice president of science and regulatory affairs at PhRMA.
About the Author Reprints
